Roche was seriously affected by coronavirus pneumonia-19 in 2020Q2, and its sales revenue showed negative growth for the first time, down by 4%. Especially in May, the sales revenue decreased by 15%.
The sales of Avastin (bevacizumab), rituximab (rituximab) and Herceptin (trastuzumab) of Roche Troika were all affected by similar drugs. Among them, Avastin's global sales in the first half of 2020 was 2.845 billion Swiss francs, down 65,438+08% year-on-year, and the sales in the US market decreased by 33%. Rituxan's global sales were 2.44 billion Swiss francs, down 23% year-on-year, and the European market fell 34%; Herceptin's global sales were 2.2 billion Swiss francs, down 28% year-on-year, and the US market dropped 42%.
2020H 1 Top 20 Sales of Roche Pharmaceuticals (100 million Swiss francs)
On the other hand, Roche's newly approved products have performed brilliantly in recent years. In the first half of the year, the sales of Perjeta (pertuzumab) reached 65,438+09.45438+0 billion Swiss francs, up 65,438+07% year-on-year. PD-L 1 drug Tecentriq is widely used for small cell lung cancer and triple negative breast cancer, and its sales amount reaches 6543.8+297 million Swiss francs, up 74% year-on-year. Although multiple sclerosis drug Ocrevus and hemophilia drug Hemlibra were seriously affected by coronavirus pneumonia-19, they still reached the growth rate of 25% and 94% respectively.
Actemra (Tozumab) was not approved for coronavirus pneumonia-19, but its sales in the first half of the year were 14. 1 100 million Swiss francs, up 36% year-on-year.
Send the PPT of Roche's financial report for the first half of 2020 to the official WeChat account.
Light up "look" and match it with good articles.